BioMarin Pharmaceutical Inc. (BMRN) - Stock Analysis
Last updated: Apr 12, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
BioMarin Pharmaceutical raised 2025 revenue guidance on strong product sales and a $4.8B accretive Amicus acquisition, supported by FDA regulatory catalysts and an 18% stock gain over 3 weeks, validating near-term positive momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong cash/FCF ⢠High operating costs ⢠Earnings volatility BMRN has a very strong liquidity and lowâleverage position with high margins and $725M FCF in FY2025, but large operating costs, quarterâtoâquarter earnings volatility and elevated valuation imply execution risk if growth or margins slip.
Price Behavior
Key Price Behavior Insights: ⢠Below moving average ⢠Defined support ⢠Whipsaw risk Support Level: $54.0â$54.8 Resistance Level: $58â$60 On the last month view BMRN is in a short-term downtrend trading at $54.53 below its ~$55.90 moving average, with support around $54.0â$54.8 that could cap losses and resistance near $58â$60 needed to reverse the bias amid heightened whipsaw risk.
Sentiment & News
Key News Insights: ⢠VOXZOGO efficacy ⢠Midâstage halt ⢠Share decline BioMarin showed strong VOXZOGO clinical validation but halted a midâstage bone program for safety, driving notable nearâterm share weakness.
AI Summary
BMRN has moved from a singleâproduct VOXZOGO growth story to an executionâdependent platform where the stock's upside now materially requires a successful Amicus integration, sustained FCF/cash conversion, and positive pivotal pipeline readouts rather than VOXZOGO alone. Monitor net debt postâclose, FY2025+ FCF trajectory (toward the ~$860m runârate), and the next pivotal readoutsâfailure on any of these would quickly force dilution or asset sales, while success would deârisk valuation.
Description
BioMarin Pharmaceutical is a biopharmaceutical company that develops and sells therapies for rare and serious genetic and metabolic disorders, with marketed treatments across lysosomal storage disorders, phenylketonuria, Batten disease, achondroplasia and related conditions. Its late-stage pipeline includes gene therapies for hemophilia A and phenylketonuria and early-stage programs for primary hyperoxaluria, while commercial operations distribute products through specialty pharmacies, hospitals and wholesalers in the U.S., Europe, Latin America and other markets. The company maintains multiple licensing and collaboration arrangements and is headquartered in San Rafael, California, having been founded in 1996.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 22 | Dec 29 | BMRN | BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical raised 2025 revenue guidance on strong product sales and a $4.8B accretive Amicus acquisition, supported by FDA regulatory catalysts and an 18% stock gain over 3 weeks, validating near-term positive momentum. | Closed | +1.3% |